Royalty Report: Drugs, Pharmaceuticals, Disease – Collection: 60410


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drugs
  • Pharmaceuticals
  • Disease
  • Therapeutic
  • Technical Know How
  • Wound Care
  • Bacterial Infection
  • Antibiotic
  • Dermatology
  • Skin care
  • Biotechnology
  • Respiratory

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 60410

License Grant
The parties entered an agreement regarding the development of Baxdela.
License Property
Baxdela, a Captisol-enabled delafloxacin-IV. Delafloxacin is a novel hospital-focused fluoroquinolone antibiotic candidate with potency against a variety of quinolone-resistant Gram-positive and Gram-negative bacteria, including quinolone-resistant Methicillin-resistant Staphylococcus aureu or MRSA.
Field of Use
Licensee is currently completing Phase 3 clinical trials for the development of  Baxdela.   In 2015, Licensee reported positive top-line results on the first of two planned Phase 3 clinical trials of delafoxacin for the treatment of Acute bacterial skin and skin structure infections (ABSSSI), including infections caused by MRSA.

IPSCIO Record ID: 4374

License Grant
Licensor hereby grants to Licensee, a UK Corporation, an exclusive sublicensable, transferrable license under the Licensor's Patents, Know-How,  Inventions and Licensor’s rights in the Joint Inventions and/or Joint Invention Patents to Commercialize the Licensed Product in the Field in the Territory.
License Property
Licensor invented a proprietary compound known as Telavancin (VIBATIV®) for the treatment of serious Gram-positive bacterial infections in humans.

VIBATIV®  is for the treatment of nosocomial pneumonia (hospital-acquired), including ventilator-associated pneumonia, known or suspected to be caused by MRSA when other alternatives are not suitable.

VIBATIV® is a bactericidal, once-daily injectable lipoglycopeptide antibiotic approved in the U.S. and Canada for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including Staphylococcus aureus, both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains.

Field of Use
Field means veterinary or human pharmaceutical use of the Licensed Product.

IPSCIO Record ID: 30410

License Grant
Granted rights are for the worldwide development and commercialization of ACH-702 delivered topically or locally.  The Agreement includes the right to sublicense any or all of the licensed rights, subject to the Licensor’s approval. In December 2012, Licensee entered into a sublicense agreement with and other company for the development of ACH-702.
License Property
ACH-702 is a novel isothiazoloquinolone (ITQ) and has been assessed for antibacterial activity against a panel of Gram-positive and Gram-negative clinical isolates and found to possess broad-spectrum activity, especially against antibiotic-resistant Gram-positive strains, including methicillin-resistant Staphylococcus aureus(MRSA).

IPSCIO Record ID: 263068

License Grant
Licensor granted Japanese Licensee the right to manufacture and procure such API and clinical supply, and forfeited rights to all future milestone payments related to Licensee’s development of solithromycin in Japan.  Under the terms of this Amended Agreement, Licensor is legally relieved of all obligations related to the supply of API or clinical supply to Licensee.
License Property
Solithromycin is an active pharmaceutical ingredient ('API') contained in our products and product candidates, as well as the preparation of finished products and their packaging for human therapeutic uses, other than for ophthalmic indications or any condition, disease or affliction of the ophthalmic tissues.

The Licensor is a commercial-stage pharmaceutical company focused on developing and commercializing differentiated anti-infectives for the hospital and select non-hospital, or community, settings that address the need for effective treatments for infections due to resistant gram-negative and gram-positive bacteria.  They currently market four antibiotics to treat a variety of infections caused by these resistant bacteria.

Solithromycin has been successfully evaluated in two Phase 3 clinical trials for community acquired bacterial pneumonia (CABP) and applications for approval for both intravenous and oral capsule formulations have been accepted for review by the FDA and the EMA.  Solithromycin is also in a Phase 3 clinical trial for uncomplicated urogenital urethritis caused by Neisseria gonorrhoeae or chlamydia.

Field of Use
Licensee owns exclusive rights to develop and commercialize solithromycin in Japan for respiratory tract infections and other indications in adults and pediatric patients.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.